Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 9/20 | 0.46 |
| ▸ | MMP9 | P14780 | 7/20 | 0.46 |
| ▸ | MMP3 | P08254 | 2/20 | 0.46 |
| ▸ | MMP13 | P45452 | 2/20 | 0.46 |
| ▸ | MMP1 | P03956 | 4/20 | 0.44 |
| ▸ | MMP14 | P50281 | 2/20 | 0.44 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.44 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.44 |
| ▸ | MMP7 | P09237 | 1/20 | 0.42 |
| ▸ | BMP1 | P13497 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1379922 | 1.00 | MMP2 (0.46) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL5034648 | 0.91 | MMP2 (0.52) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL1380534 | 0.90 | MMP2 (0.54) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL1380533 | 0.90 | MMP2 (0.54) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL5033703 | 0.85 | MMP2 (0.44) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL5033708 | 0.85 | MMP2 (0.44) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL1376076 | 0.83 | MMP2 (0.53) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL6784899 | 0.82 | MMP2 (0.53) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL1379461 | 0.81 | MMP2 (0.52) | MMP2MMP9MMP3MMP13MMP1 | |
| SCHEMBL7423437 | 0.81 | MMP2 (0.41) | MMP2MMP9MMP3MMP13MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4750272-B2 | — | — | 2011-08-17 | — | — | JP | claimed |
| EP-1918278-A1 | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases | Novartis AG (CH) | 2008-05-07 | — | — | EP | claimed |
| EP-1053226-A1 | SULFONYLAMINO DERIVATIVES WHICH INHIBIT MATRIX-DEGRADING METALLOPROTEINASES | Novartis AG (CH) | 2000-11-22 | — | — | EP | claimed |
| WO-1999042443-A1 | SULFONYLAMINO DERIVATIVES WHICH INHIBIT MATRIX-DEGRADING METALLOPROTEINASES | NOVARTIS AG (CH) | 1999-08-26 | — | — | WO | claimed |
| EP-1918278-A1 | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases | Novartis AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| US-6410580-B1 | ANTIINFLAMMATORY AGENTS, RHEUMATIC DISEASES | NOVARTIS AG (CH) | 2002-06-25 | — | — | US | disclosed |
| EP-1053226-A1 | SULFONYLAMINO DERIVATIVES WHICH INHIBIT MATRIX-DEGRADING METALLOPROTEINASES | Novartis AG (CH) | 2000-11-22 | — | — | EP | disclosed |
| WO-1999042443-A1 | SULFONYLAMINO DERIVATIVES WHICH INHIBIT MATRIX-DEGRADING METALLOPROTEINASES | NOVARTIS AG (CH) | 1999-08-26 | — | — | WO | disclosed |